COVID 19

Mitsubishi Corporation, KDDI CORPORATION, Lawson, Inc. have entered into the Capital Business Partnership Agreement

Retrieved on: 
Tuesday, February 6, 2024

Lawson and KDDI will merge their real touchpoints (Lawson stores: approximately 14,600, au Style/au shop stores: approximately 2,200) to establish large real-store networks in Japan.

Key Points: 
  • Lawson and KDDI will merge their real touchpoints (Lawson stores: approximately 14,600, au Style/au shop stores: approximately 2,200) to establish large real-store networks in Japan.
  • This will enable Lawson to expand its store network and enhance its functionalities, aiming for further improvement in customer convenience.
  • - Developing services for KDDI and Lawson customers to provide good shopping deals, expanding customer visits to Lawson stores.
  • KDDI is expanding into a wide range of business areas including mobile telecommunications as core business, as well as banking, insurance, education, travel, and delivery services.

Intelligence doesn’t make you immune to conspiracy theories – it’s more about thinking style

Retrieved on: 
Tuesday, January 30, 2024

Some conspiracy theories, for example the QAnon conspiracy, can be considered a minority belief, with a 2021 YouGov poll showing that 8% of those polled in the UK endorsed this conspiracy theory.

Key Points: 
  • Some conspiracy theories, for example the QAnon conspiracy, can be considered a minority belief, with a 2021 YouGov poll showing that 8% of those polled in the UK endorsed this conspiracy theory.
  • People with high education levels, such as doctors and nurses, have been reported to propagate conspiracy theories.
  • Read more:
    How morbid curiosity can lead people to conspiracy theories

Critical thinking


Research shows that our thinking style can be predictive of susceptibility to conspiracy theories. The dual processing theory of cognitive style suggests that we have two routes which we can use to process information. One route is the fast, intuitive route which leans more on personal experiences and gut feelings. The other route is a slower, more analytical route which instead relies on elaborative and detailed processing of information.

  • It also found those who were less likely to engage in effortful thinking styles and more likely to use intuitive thinking showed a higher belief in conspiracy theories.
  • Critical thinking is a valuable skill, particularly within education, and has been shown to buffer susceptibility to conspiracy beliefs.

Thinking style is not the same as intelligence

  • A 2021 meta-analysis study indicates that an intuitive thinking style is unrelated to intelligence.
  • So, even really smart people could be susceptible to conspiracy beliefs – if they are more inclined to revert to faster, intuitive thinking styles.
  • First, conspiracy beliefs seem to be predicted by the flawed belief that big events must have big consequences.
  • This is how thinking styles reliant on gut feelings and intuition can lead people to endorse conspiracy theories.
  • However, these studies are helping researchers find interventions which can increase analytical and critical thinking styles and so buffer against susceptibility to such beliefs.


Darel Cookson does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

T-Mobile Strengthens Hawaii and Washington Nonprofit Organizations with $50,000 in Donations

Retrieved on: 
Monday, January 29, 2024

T-Mobile (NASDAQ: TMUS) today announced a donation totaling $50,000 to two Hawaii and three Washington nonprofit organizations that are making a difference in their communities.

Key Points: 
  • T-Mobile (NASDAQ: TMUS) today announced a donation totaling $50,000 to two Hawaii and three Washington nonprofit organizations that are making a difference in their communities.
  • The organizations — Ferndale Food Bank, Generating Hope, Habitat for Humanity Seattle–King & Kittitas Counties (SKKC), Maui Food Bank and the Maui Strong Foundation — each received $10,000.
  • T-Mobile and these five organizations are all better for their outstanding efforts.”
    Here’s a closer look at how T-Mobile's donations are making a difference.
  • These donations underscore T-Mobile’s ongoing commitment to making a difference in communities throughout Hawaii and Washington.

Phalanx Impact Partners Announces Strategic Investment in Dallas-Based FinTech Company CollateralEdge

Retrieved on: 
Monday, January 15, 2024

Phalanx Impact Partners (“Phalanx”), an innovative new investment firm dedicated to positive environmental and community change, proudly announces its investment in CollateralEdge, a revolutionary FinTech solution that enables community and regional banks to structure more competitive commercial loans for underserved communities and close more deals without compromising credit quality.

Key Points: 
  • Phalanx Impact Partners (“Phalanx”), an innovative new investment firm dedicated to positive environmental and community change, proudly announces its investment in CollateralEdge, a revolutionary FinTech solution that enables community and regional banks to structure more competitive commercial loans for underserved communities and close more deals without compromising credit quality.
  • This investment communicates Phalanx’s thesis that expanded access to middle market credit solutions benefits our next generation of entrepreneurs in all communities.
  • "CollateralEdge's vision deeply resonated with our belief that expanded access to credit can transform communities,” said John Pantalena, Partner at Phalanx Impact Partners.
  • “Our collaboration with Phalanx Impact Partners is a testament to our shared belief in the economic backbone of the country—small businesses.

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

Retrieved on: 
Tuesday, January 9, 2024

NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to SLS009 (formerly GFH009), its novel and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML). The Fast Track Designation is intended to facilitate the development and review of drugs to treat serious conditions and fill an unmet medical need.

Key Points: 
  • The Fast Track Designation is intended to facilitate the development and review of drugs to treat serious conditions and fill an unmet medical need.
  • Importantly, as of the last follow-up, eight of the nine patients enrolled in the 45 mg cohort were alive.
  • The first patient enrolled in the study achieved a complete response (CR) and continues on study in the seventh month with full peripheral blood recovery.
  • Eight patients (89%) remain alive (one patient succumbed to sepsis having previously contracted COVID 19) and six continue treatment.

Human medicines European public assessment report (EPAR): Veklury, remdesivir, Date of authorisation: 03/07/2020, Revision: 23, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Veklury, remdesivir, Date of authorisation: 03/07/2020, Revision: 23, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Veklury, remdesivir, Date of authorisation: 03/07/2020, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir,ritonavir, Date of authorisation: 28/01/2022, Revision: 16, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir,ritonavir, Date of authorisation: 28/01/2022, Revision: 16, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir,ritonavir, Date of authorisation: 28/01/2022, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine,elasomeran,elasomeran / imelasomeran,elasomeran / davesomeran,andusomeran, Date of authorisation: 06/01/2021, Revision: 41[...]

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine,elasomeran,elasomeran / imelasomeran,elasomeran / davesomeran,andusomeran, Date of authorisation: 06/01/2021, Revision: 41, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine,elasomeran,elasomeran / imelasomeran,elasomeran / davesomeran,andusomeran, Date of authorisation: 06/01/2021, Revision: 41, Status: Authorised

SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia

Retrieved on: 
Thursday, December 14, 2023

NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the first patients have been enrolled in the 60 mg dose cohort in its ongoing Phase 2a clinical trial of its novel and highly selective CDK9 inhibitor, SLS009, in combination with venetoclax and azacitidine (aza/ven) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) who did not respond or stopped responding to venetoclax-based therapies.

Key Points: 
  • A total of nine patients have been enrolled at the 45 mg safety dose level.
  • Eight patients remain alive (one patient succumbed to sepsis having previously contracted COVID 19) and six continue treatment.
  • The first enrolled patient achieved a complete response and is currently in the seventh month of treatment and the second enrolled patient is in the sixth month of treatment.
  • In the 60 mg dose cohort, patients will be randomized to one of two groups, 60 mg flat (fixed) dose once per week and 30 mg fixed dose two times per week.

NeoVolta Reports Q4 Sales Surge As Popular NV14 Home Solar Energy Storage Battery Shows Near Six-Figure Gross Revenues Over Last Six Weeks

Retrieved on: 
Monday, November 13, 2023

NeoVolta is proud to include new installers as part of a new direct marketing campaign that is gaining traction.

Key Points: 
  • NeoVolta is proud to include new installers as part of a new direct marketing campaign that is gaining traction.
  • “We see that the independent solar dealer/installers had to make changes in the new NEM3 environment, and we are welcoming them as certified installers of NeoVolta home energy storage solution - a growing must in home solar energy solutions,” Willson added.
  • NeoVolta’s NV14 system was recognized as one of Solar Power World’s Top Solar Storage Products for the third year in a row.
  • The company also earned accolades in April 2022, as the NV14 was named one of the most affordable solar batteries in the U.S. in EnergySage’s latest semi-annual Solar Marketplace Intel Report .